In our previous study, we demonstrated that interleukin-10 and interleukin-12 (p70) levels, in combination with clinical variables, at hospital admission are key biomarkers associated with an increased risk of disease progression in hypertensive patients with COVID-19, and we proposed a biomarker-based approach to improve the prediction of this risk [11]. The gene discussed is IL10; the disease is COVID-19.